AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03827161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Study NCT00282347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02243423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SUPINE
Description: Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline.
Study NCT02243423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TILT
Description: Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline.
Study NCT04176042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Track 1
Description: Intervention + Follow-up
Study NCT04176042 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Track 2
Description: Wait list + Intervention
Study NCT02996032 — intervention group
Intervention type: OTHER
Intervention: Vascular and Pulmonary Ultrasound
Study NCT03337789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polygonatum sibiricum
Description: Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
Study NCT03337789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
Study NCT00859027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35 mg/week by mouth
Study NCT00859027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo risedronate oral tablet
Description: One tablet by mouth every week as directed
Study NCT01128023 — intervention group
Intervention type: OTHER
Intervention: Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT
Description: Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
Study NCT02386670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS + CR
Description: First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely).
Study NCT02386670 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS + sham CR
Description: First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz \& cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely).
Study NCT03467100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XEN901
Description: Capsule filled with XEN901
Study NCT03467100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert Ingredients Oral Product
Description: Placebo capsule
Study NCT04316975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Study Driven Procurement of Biopsies
Description: Four research biopsies collected at the midpoint of current BE or IMC at Baseline and after reaching CEIM. Biopsies will be used to calculate ML scores both pre and post EET.
Study NCT01449942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNAzyme targeting EBV-LMP1 (DZ1)
Description: DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.
Study NCT01449942 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DNAzyme targeting EBV-LMP1 (DZ1)
Description: DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.
Study NCT01396369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Birth control
Description: In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
Study NCT01396369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birth control plus Brevail
Description: In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
Study NCT02618369 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MR-Guided High Intensity Focused Ultrasound
Description: Target treatment of bone lesion using High Intensity Focused Ultrasound
Study NCT02866864 — intervention group
Intervention type: OTHER
Intervention: Animal allergy +
Description: Allergic symptom occurs when subject contact animal
Study NCT01449942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: 0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.
Study NCT01449942 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks.
Study NCT03337828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol-free beer with regular composition
Description: Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
Study NCT03337828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-free beer with modified composition
Description: Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
Study NCT04113369 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS
Description: 30 minutes of conventional antalgic TENS to non-paretic forearm
Study NCT04113369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: 40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
Study NCT04113369 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional rehabilitation
Description: 40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
Study NCT04113369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: 20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
Study NCT05206656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eribulin Mesylate
Description: Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
Study NCT05206656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Eribulin mesylate injection is performed on Day 1 and Day 8 of each treatment cycle (21 days per cycle). Patients were treated for six cycles, except disease progression (PD) or treatment stop for other reasons, such as severe adverse effects.
Study NCT05206656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12 mg Anlotinib is administered for continuous 14 days in 21 day cycles. Patients received Anlotinib untill disease progression.
Study NCT02058745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAU+ (Enhanced Care as Usual)
Description: CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period.
Study NCT02058745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAU+ (Enhanced Care as Usual)
Description: CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period.
Study NCT02058745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson.
Study NCT02866864 — intervention group
Intervention type: OTHER
Intervention: Animal allergy -
Description: Allergic symptom does not occur when subject contact animal
Study NCT02514759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Teen Outreach Program
Description: Students received the Teen Outreach Program as described previously.
Study NCT00550537 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: Blood and tissue collection.
Study NCT02058745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SmartCare
Description: SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
Study NCT00550537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood and tissue collection.
Study NCT00306462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is \< 6/hour.
Study NCT00306462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nifedipine or placebo
Description: Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is \< 6/hour.
Study NCT01523730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
Study NCT01523730 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Repetitive Transcranial Stimulation (rTMS)
Description: Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection
Study NCT01916291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propess insertion group
Study NCT02412813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LEGION OXINIUM
Description: Investigational Group
Study NCT02412813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LEGION Cobalt Chrome
Description: Control Group
Study NCT02031328 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Solution for injection, Subcutaneous injection
Study NCT00317291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture/Moxibustion
Description: Acupuncture/Moxibustion: 16 scheduled sessions
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Solution for injection, Subcutaneous injection
Study NCT01854047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA therapy
Description: Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
Study NCT00317291 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture/Placebo moxibustion
Description: Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
Study NCT02006095 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
Study NCT02006095 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological testing
Study NCT04441190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Action Observation Therapy (Digital AOT)
Description: The participants will be asked to observe videos and then practice what the participants observed.
Study NCT04441190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Mirror Therapy (Digital MT)
Description: The participants will observe the real-time self-recorded visual illusion, and move their upper limbs as could as possible.
Study NCT04441190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy
Description: The participants will receive upper-limb training without providing videos for observing neither providing them mirror illusions of movements.
Study NCT03472547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein 1% ointment
Description: All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
Study NCT01949467 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: iron fumarate
Description: All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
Study NCT01957956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00535288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
Study NCT00535288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
Study NCT01822314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
Study NCT01822314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
Study NCT05181280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Exposure session will consist of 15 social media ideal body message posts.
Study NCT05181280 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Exposure will consist of 15 social media posts on infant feeding tips.